Translational research studies of erbB oncogenes: selection strategies for breast cancer treatment

Cancer Lett. 1997 Oct 14;118(2):143-51. doi: 10.1016/s0304-3835(97)00324-8.


Specific gene families, e.g. encoding members of signal transduction pathways, show a gene dosage sensitivity. We report on the determination of the gene dosages of egfr and c-erbB-2 in relation to the intratumoral concentration of the tyrosine kinase receptor protein EGFR and p185c-erbB-2 and the clinical outcome of breast cancer patients in a retrospective study. Prognostic unfavorable subgroups were determined in a life-table analysis by (a) an average gene copy number of egfr of less than 0.4 and greater than 1.6 and an intratumoral EGFR concentration of more than 56 fmol/mg, (b) an intratumoral p185c-erbB-2 concentration above 26 HNU/mg and (c) a quotient of egfr and c-erbB-2 average gene copy numbers of less than 0.15 and greater than 4.35.

MeSH terms

  • Breast Neoplasms / genetics*
  • Breast Neoplasms / pathology
  • DNA Replication
  • DNA, Neoplasm / genetics
  • Disease-Free Survival
  • ErbB Receptors / genetics*
  • Gene Amplification
  • Gene Dosage
  • Genes, erbB*
  • Humans
  • Loss of Heterozygosity
  • Neoplasm Metastasis
  • Prognosis
  • Receptor, ErbB-2 / genetics*


  • DNA, Neoplasm
  • ErbB Receptors
  • Receptor, ErbB-2